Snapshot of transurethral resection of bladder tumours in the United Kingdom Audit (STUKA)

BJU International

Volumn 112, Issue 7, 2013, Pages 930-935

  Gan, Christine ^a   Patel, Amit ^a   Fowler, Sarah ^a   Catto, James ^a   Rosario, Derek ^a   O'Brien, Timothy ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

bladder cancer; quality; transurethral resection of bladder tumour

Indexed keywords

MITOMYCIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BLADDER PERFORATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CARCINOMA IN SITU; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; QUALITY CONTROL; TRANSURETHRAL RESECTION; TRANSURETHRAL RESECTION OF BLADDER TUMOR; UNITED KINGDOM; UROLOGIST;

BLADDER CANCER; QUALITY; TRANSURETHRAL RESECTION OF BLADDER TUMOUR;

ADULT; AGED; AGED, 80 AND OVER; CYSTECTOMY; FEMALE; GREAT BRITAIN; HUMANS; MALE; MEDICAL AUDIT; MIDDLE AGED; URETHRA; URINARY BLADDER NEOPLASMS;

EID: 84886010732     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12235     Document Type: Article

References (22)

1. O'Brien T, Viney R, Doherty A, Thomas K,. Why don't Mercedes Benz publish randomized trials? BJU Int 2010; 105: 293-295
2. Cancer Research UK. Bladder cancer incidence statistics. Available at: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/bladder/incidence/ . Accessed 25 January 2013
3. Bas WG, van Rhijn MB,. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009; 56: 430-442
4. Bryan RT, Collins SI, Daykin MC, et al. Mechanisms of recurrence of Ta/T1 bladder cancer. Ann R Coll Surg Engl 2010; 92: 519-524
5. Herr H,. Role of re-resection in non-muscle invasive bladder cancer. ScientificWorldJournal 2011; 11: 283-288
6. Solsona E, Iborra I, Ricos JV, Monros J, Casanova J, Dumont R,. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up. J Urol 1999; 161: 1120-1123
7. Brausi M, Collette L, Kurth KH, et al. Variability in the recurrence rate at first follow up cystoscopy after TUR in stage TaT1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002; 41: 523-531
8. Gallimore SC, Hoile RW, Ingram GS, Sherry KM,. The Report of the National Confidential Enquiry into Perioperative Deaths 1994/1995. NCEPOD 1997. Available at: http://www.ncepod.org.uk/pdf/1994-5/Full%20Report%201994-1995.pdf. Accessed 23 December 2012
9. Institute of Medicine. Crossing the Quality Chasm. A New Health System for the 21st Century. Washington DC: National Academy Press, 2001
10. Mostafid H, Brausi M,. Measuring and improving the quality of transurethral resection for bladder tumour (TURBT). BJU Int 2011; 109: 1579-1582
11. Herr HW, Donat SM,. Quality control in transurethral resection of bladder tumours. BJU Int 2008; 102: 1242-1246
12. Bladder Cancer Clinical Guideline Update Panel, American Urological Association. Bladder cancer: guideline for the management of non-muscle invasive bladder cancer: (stages Ta, T1, and Tis): 2007 update. Available at: http://www.auanet.org/common/pdf/education/clinical-guidance/Bladder-Cancer.pdf. Accessed July 2013
13. Babjuk M, Oosterlinck W, Sylvester R, et al. Guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). Uroweb 2012. Available at: http://www.uroweb.org/gls/pdf/05-TaT1-Bladder-Cancer-LR%20March%2013th%202012. pdf. Accessed 12 December 2012
14. Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009; 250: 187-196
15. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466-477
16. Mariappan P, Finney SM, Head E, et al. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int 2012; 109: 1666-1673
17. Bladder tumour resection-procedure specific information for patients. BAUS, 2012. Available at: http://www.baus.org.uk/Resources/BAUS/Documents/ PDF%20Documents/Patient%20information/TURBT.pdf. Accessed 23 December 2012
18. Mariappan P, Zachou A, Grigor KM,. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 2010; 57: 843-849
19. Maruniak NA, Takezawa K, Murphy WM,. Accurate pathological staging of urothelial neoplasms requires better cystoscopic sampling. J Urol 2002; 167: 2404-2407
20. Herr HW, Donat SM,. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 2006; 97: 1194-1198
21. Witjes JA, Redorta JP, Jacqmin D, et al. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. Eur Urol 2010; 57: 607-614
22. O'Brien T, Thomas K,. Bladder cáncer: photodynamic diagnosis can improve surgical outcome. Nat Rev Urol 2010; 7: 598-599